Ascierto PA - Search Results

1

Who benefits most from adjuvant interferon treatment for melanoma?

Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E. Gogas H, et al. Among authors: ascierto pa. Am J Ther. 2015 Jan-Feb;22(1):54-60. doi: 10.1097/MJT.0b013e31829e883d. Am J Ther. 2015. PMID: 24176884 Review.

2

3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma.

Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G. Ascierto PA, et al. Int J Mol Med. 1999 Mar;3(3):303-6. doi: 10.3892/ijmm.3.3.303. Int J Mol Med. 1999. PMID: 10028056 Clinical Trial.

3

Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.

Ascierto PA, Palmieri G, Strazzullo M, Daponte A, Botti G, Satriano SM, Motti ML, Mozzillo N. Ascierto PA, et al. Ann Oncol. 2000 Apr;11(4):487-90. doi: 10.1023/a:1008375418507. Ann Oncol. 2000. PMID: 10847472 Free article. No abstract available.

4

Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.

Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.

5

Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up.

Mozzillo N, Caracò C, Chiofalo MG, Celentano E, Lastoria S, Botti G, Ascierto PA. Mozzillo N, et al. Among authors: ascierto pa. Eur J Surg Oncol. 2004 May;30(4):440-3. doi: 10.1016/j.ejso.2004.01.020. Eur J Surg Oncol. 2004. PMID: 15063899

6

Adjuvant treatment of malignant melanoma: where are we?

Ascierto PA, Scala S, Ottaiano A, Simeone E, de Michele I, Palmieri G, Castello G. Ascierto PA, et al. Crit Rev Oncol Hematol. 2006 Jan;57(1):45-52. doi: 10.1016/j.critrevonc.2005.05.002. Epub 2005 Jun 28. Crit Rev Oncol Hematol. 2006. PMID: 15990330 Review.

7

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. Ascierto PA, et al. J Clin Oncol. 2005 Oct 20;23(30):7660-8. doi: 10.1200/JCO.2005.02.0933. J Clin Oncol. 2005. PMID: 16234528 Clinical Trial.

8

Soluble interleukin-2 receptor in stage I-III melanoma.

Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, Bryce J, Caracò C, Satriano RA, Gianfranco N, Franco R, Botti G, Castello G. Ottaiano A, et al. Among authors: ascierto pa. Cytokine. 2006 Feb 7;33(3):150-5. doi: 10.1016/j.cyto.2006.01.002. Epub 2006 Mar 6. Cytokine. 2006. PMID: 16517174

9

Adjuvant therapy of melanoma with interferon: lessons of the past decade.

Ascierto PA, Kirkwood JM. Ascierto PA, et al. J Transl Med. 2008 Oct 27;6:62. doi: 10.1186/1479-5876-6-62. J Transl Med. 2008. PMID: 18954464 Free PMC article. Review.

10

Melanoma: a model for testing new agents in combination therapies.

Ascierto PA, Streicher HZ, Sznol M. Ascierto PA, et al. J Transl Med. 2010 Apr 20;8:38. doi: 10.1186/1479-5876-8-38. J Transl Med. 2010. PMID: 20406483 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

684 results

Search Page